Search Results for: 19

Want to learn more? We’d love to hear from you. US Headquarters 9605 Medical Center Dr. Suite 270 Rockville, MD 20850 European Office Theriva™ Biologics SL Carrer Torrent de Can Ninou, naus 5-6 08150 – Parets del Vallès (Barcelona) Spain Email info@therivabio.com

WORK AT THERIVA™ As we grow, we continue to seek talented and driven scientists, marketers, analysts, and engineers who share in our mission. We are a collaborative, generous, and committed team that is devoted to leveraging the unique perspectives of every team member in our efforts to develop first-in-class cancer therapies. While there are no

OVERVIEW Theriva™ Biologics’ oncolytic viruses have the potential to treat a broad range of difficult-to-treat tumor types and may be combined with a variety of cancer therapies. In the on-going VIRAGE Phase 2 clinical trial in patients with PDAC, VCN-01 is being tested in combination with standard-of-care chemotherapy gemcitabine/nab-paclitaxel. VCN-01 was also administered with the

The Theriva™ Difference Theriva is developing highly differentiated oncolytic adenoviruses that are designed to overcome the challenges of accessibility, availability, and administration and can potentially enable multiple dosing to improve efficacy. The unique therapeutic properties of Theriva’s oncolytic viruses represent a new class of cancer treatments that are designed to selectively destroy tumor cells and

Overview Theriva™ is a clinical-stage immuno-oncology company developing oncolytic viruses intended to overcome the protective barrier surrounding solid tumors and selectively kill tumor cells. Our developmental therapies stem from the laboratory of Dr. Ramon Alemany, recognized world-wide as a key opinion leader in adenovirus technologies, and are designed to enable systemic delivery and have the

The information in this website contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended, on Theriva™ Biologics’ current expectations and projections about future events. In some cases forward-looking statements can be identified by terminology

DELIVERING A NEW CLASS OF ONCOLYTIC VIRUS THERAPEUTICS ABOUT THERIVA™ Theriva is a clinical-stage immuno-oncology company developing oncolytic viruses intended to overcome the protective barrier surrounding solid tumors and selectively kill tumor cells. Our developmental therapies are designed to enable systemic delivery and have the potential to enhance current standard-of-care therapies, offering patients with difficult-to-treat

UPCOMING EVENTS PAST EVENTS

What is Theriva™ Biologics stock symbol? Our stock is traded on the NYSE American under the symbol TOVX. Can I buy stock directly from Theriva Biologics? No, you will need to contact a licensed stock broker or use an online trading account. Where is Theriva Biologics located? 9605 Medical Center Dr.Suite 270Rockville, MD 20850 When